MyFinsight
Home
Blog
About
Cash and cash
equivalents
$63,008K
(-65.59%↓ Y/Y)
Restricted cash
$42K
(0.00%↑ Y/Y)
Short-term investments
$263,273K
Total cash, cash
equivalents and restricted...
$63,050K
(-65.57%↓ Y/Y)
Prepaid expenses and
other current assets
$5,151K
(17.15%↑ Y/Y)
Accounts and other
receivables
$3,341K
(940.81%↑ Y/Y)
Total current assets
$334,815K
(77.69%↑ Y/Y)
Long-term investments
$192,247K
Other assets
$90K
(-94.25%↓ Y/Y)
Property and equipment,
net
$60K
(-83.52%↓ Y/Y)
Total assets
$527,212K
(176.97%↑ Y/Y)
Total liabilities and
stockholders' equity
$527,212K
(176.97%↑ Y/Y)
Total stockholders'
equity
$474,208K
(193.87%↑ Y/Y)
Total liabilities
$53,004K
(82.88%↑ Y/Y)
Accumulated deficit
-$694,871K
(-15.21%↓ Y/Y)
Accumulated other
comprehensive loss, net
-$6,038K
(-19.83%↓ Y/Y)
Additional paid-in capital
$1,175,098K
(52.71%↑ Y/Y)
Term loan,
noncurrent
$34,742K
(142.41%↑ Y/Y)
Total current
liabilities
$12,501K
(35.59%↑ Y/Y)
Other noncurrent
liabilities
$5,761K
(6.08%↑ Y/Y)
Common stock, 0.0001
par value...
$19K
(111.11%↑ Y/Y)
Accrued expenses and
other current...
$11,229K
(34.17%↑ Y/Y)
Accounts payable
$1,272K
(49.47%↑ Y/Y)
Back
Back
Balance Sheet
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)
source: myfinsight.com